comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists The effects of receptor beyond obesity type 2 diabetes: An anti-atherosclerotic action GLP-1 Receptor Agonists in Heart
Description
Although the effects of GLP-1 are mostly consistent with an anti-atherogenic function, GIP may have opposing effects that may be viewed as pro-atherogenic
Addressing Broader Health Concerns Related to GLP-1 Drugs So far, researchers have only studied GLP-1 drugs in randomized clinical trials in the context of diabetes and obesity
PMID: 21562063
Eli Lillys orforglipron is the furthest advanced, in late-stage clinical trials with potential FDA approval in 2026
Pharmacotherapy (2011) 31:896911
The 31-year-old compliance consultant from Hendersonville, Tennessee, said she couldnt stop vomiting
